Revenue grew 3% to $276m with stable EBITDA, but NPAT declined due to investment and one-off costs. Strong growth in MHL and minerals offset protein segment weakness; forward work and strategic investments support a positive outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.